Reoperation for hematoma in patients on perioperative antithrombotic drugs underwent thyroidectomy

IF 1.8 4区医学 Q2 OTORHINOLARYNGOLOGY

American Journal of Otolaryngology Pub Date : 2025-04-21 DOI:10.1016/j.amjoto.2025.104636

Bassam Abboud , Christopher Abboud , Mayssam Meouche

{"title":"Reoperation for hematoma in patients on perioperative antithrombotic drugs underwent thyroidectomy","authors":"Bassam Abboud , Christopher Abboud , Mayssam Meouche","doi":"10.1016/j.amjoto.2025.104636","DOIUrl":null,"url":null,"abstract":"<div><h3>Backgrounds</h3><div>Evaluate the risk of reoperation for postoperative hematoma (POH) in patients on antithrombotic conditions underwent thyroidectomy.</div></div><div><h3>Methods</h3><div>Three groups: Groups 1, 2, and 3 included thyroidectomy without treatment, under antiplatelet and anticoagulation drugs, respectively. Occurrence of POH identified 2 groups: hematoma (Group A) and no hematoma (Group B).</div></div><div><h3>Results</h3><div>The overall incidence of POH was 6 %(reoperation 0.1 %, conservative 5.9 %). 83 % of the reoperation for POH occurred within the first 24 h. Antiplatelet and anticoagulant drugs were associated with a 3.4 and 5.2 increased odds of POH respectively. Hyperthyroidism, substernal goiter, hypertension, and antithrombotic drugs were present in 32 % and 7 %, 33 % and 11 %, 52 % and 27 %, and 30 % and 9 % of patients in groups A and B respectively. Reoperation was necessary in 0.08 %, 0.23 %, and 1 % of patients in groups 1, 2, and 3 respectively.</div></div><div><h3>Conclusions</h3><div>Patients underwent thyroidectomy under antithrombotic drugs are at much higher risk for reoperation for POH.</div></div>","PeriodicalId":7591,"journal":{"name":"American Journal of Otolaryngology","volume":"46 4","pages":"Article 104636"},"PeriodicalIF":1.8000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Otolaryngology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0196070925000390","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Backgrounds

Evaluate the risk of reoperation for postoperative hematoma (POH) in patients on antithrombotic conditions underwent thyroidectomy.

Methods

Three groups: Groups 1, 2, and 3 included thyroidectomy without treatment, under antiplatelet and anticoagulation drugs, respectively. Occurrence of POH identified 2 groups: hematoma (Group A) and no hematoma (Group B).

Results

The overall incidence of POH was 6 %(reoperation 0.1 %, conservative 5.9 %). 83 % of the reoperation for POH occurred within the first 24 h. Antiplatelet and anticoagulant drugs were associated with a 3.4 and 5.2 increased odds of POH respectively. Hyperthyroidism, substernal goiter, hypertension, and antithrombotic drugs were present in 32 % and 7 %, 33 % and 11 %, 52 % and 27 %, and 30 % and 9 % of patients in groups A and B respectively. Reoperation was necessary in 0.08 %, 0.23 %, and 1 % of patients in groups 1, 2, and 3 respectively.

Conclusions

Patients underwent thyroidectomy under antithrombotic drugs are at much higher risk for reoperation for POH.

查看原文本刊更多论文

甲状腺切除术围手术期抗栓药物治疗患者血肿再手术

背景：评估抗血栓患者行甲状腺切除术后血肿（POH）再手术的风险。方法：1、2、3组分别为不加治疗的甲状腺切除术、抗血小板和抗凝药物治疗组。结果两组患者POH发生率分别为血肿组（A组）和无血肿组（B组）。结果POH总发生率为6%（再手术发生率为0.1%，保守发生率为5.9%）。83%的POH再次手术发生在第一个24小时内。抗血小板和抗凝药物分别与POH发生率增加3.4和5.2相关。甲亢、胸骨下甲状腺肿、高血压和抗血栓药物分别占A组和B组患者的32%和7%、33%和11%、52%和27%、30%和9%。第1组、第2组和第3组分别有0.08%、0.23%和1%的患者需要再次手术。结论抗栓药物治疗下行甲状腺切除术的患者POH再次手术的风险较高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Otolaryngology 医学-耳鼻喉科学

CiteScore

4.40

自引率

4.00%

发文量

378

审稿时长

41 days

期刊介绍： Be fully informed about developments in otology, neurotology, audiology, rhinology, allergy, laryngology, speech science, bronchoesophagology, facial plastic surgery, and head and neck surgery. Featured sections include original contributions, grand rounds, current reviews, case reports and socioeconomics.